CD14 and rheumatoid arthritis: The study also extends our findings, demonstrating that Tyro3TK has a distinct role in regulating CD14+CD16− monocyte osteoclastogenesis, suggesting that Tyro3TK might be a possible therapeutic target for RA bone destruction.